The Race for Clinical Trials: Can the FDA’s New Pilot Program Stop the U.S. from Falling Behind?

Start
The United States is losing ground in the global competition for clinical trials—and U.S. regulators are taking notice. On August 6, 2026, the FDA held an educational webinar on its proposed Expedited Investigational New Drug (IND) Pilot Program, a centerpiece of the Department of Health and Human Services’ broader Operation TrialBlazer initiative (FDA, Educational Webinar: Expedited IND Pilot Program, Aug. 6, 2026)….
By: Foley Hoag LLP
Previous Story

Fortune 500 Companies’ Credentials Leaking at an Alarming Rate